Tag:
Intersect ENT
Latest Headlines
Latest Headlines
Intersect ENT sees positive data on Propel from pivotal trial
Last month , we reported on Intersect ENT, which had obtained the FDA's ok for the Propel mometasone furoate implant that offers localized, controlled drug delivery for chronic sinusitis patients.
Intersect ENT CEO discusses Propel implant
Last week, Intersect ENT garnered the FDA's ok for the Propel mometasone furoate implant that offers localized, controlled drug delivery for chronic sinusitis patients. FierceMedicalDevices recently
Drug-eluting sinus implant gets FDA premarket approval
Palo Alto, CA-based Intersect ENT has earned FDA premarket approval for its Propel drug-eluting implant for treatment of chronic sinusitis. The company says Propel is the first in a new category of
Intersect raises $30M for sinus treatment
Palo Alto, CA-based Intersect ENT has raised $30 million with the help of new investor Medtronic and existing investors PTV Sciences, Kleiner Perkins Caufield & Byers and U.S. Venture Partners.
